We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

118 hedge funds and large institutions have $186M invested in Aldeyra Therapeutics in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 39 increasing their positions, 24 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 24

50% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 16

40% more call options, than puts

Call options by funds: $5.07M | Put options by funds: $3.63M

5% more funds holding

Funds holding: 112118 (+6)

0.69% more ownership

Funds ownership: 61.76%62.45% (+0.69%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

6% less capital invested

Capital invested by funds: $196M → $186M (-$10.8M)

Holders
118
Holders Change
+6
Holders Change %
+5.36%
% of All Funds
1.55%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
24
Increased
39
Reduced
24
Closed
16
Calls
$5.07M
Puts
$3.63M
Net Calls
+$1.44M
Net Calls Change
+$85K
Name Holding Trade Value Shares
Change
Change in
Stake
AA
51
AlphaCentric Advisors
Puerto Rico
$234K +$241K +46,913 New
Simplex Trading
52
Simplex Trading
Illinois
$225K +$232K +45,232 New
American Century Companies
53
American Century Companies
Missouri
$196K -$244K -47,511 -55%
Citigroup
54
Citigroup
New York
$193K +$11.8K +2,302 +6%
First Manhattan
55
First Manhattan
New York
$173K
T. Rowe Price Associates
56
T. Rowe Price Associates
Maryland
$161K -$121K -23,517 -42%
JPLA
57
Joseph P. Lucia & Associates
New York
$158K -$318 -62 -0.2%
Invesco
58
Invesco
Georgia
$149K -$3.22M -626,604 -95%
MIM
59
MetLife Investment Management
New Jersey
$143K
Mirae Asset Global ETFs Holdings
60
Mirae Asset Global ETFs Holdings
Hong Kong
$143K +$7.77K +1,515 +6%
BFM
61
Boston Financial Management
Massachusetts
$141K +$145K +28,248 New
PWA
62
Providence Wealth Advisors
Illinois
$133K
JP Morgan Chase
63
JP Morgan Chase
New York
$127K +$8.1K +1,578 +7%
CF
64
Corebridge Financial
Texas
$124K -$9.6K -1,870 -7%
IIM
65
INTECH Investment Management
Florida
$119K +$47.1K +9,178 +63%
TFA
66
Tobias Financial Advisors
Florida
$118K
SG Americas Securities
67
SG Americas Securities
New York
$112K +$14.5K +2,822 +14%
CAPTRUST Financial Advisors
68
CAPTRUST Financial Advisors
North Carolina
$103K +$7.36K +1,434 +7%
HP
69
Hikari Power
Japan
$100K
Manulife (Manufacturers Life Insurance)
70
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$95.6K -$7.86K -1,532 -7%
LWM
71
Laidlaw Wealth Management
New York
$90.7K
LBA
72
Letko, Brosseau & Associates
Quebec, Canada
$86.3K +$88.8K +17,300 New
VOYA Investment Management
73
VOYA Investment Management
Georgia
$79.8K -$4.38K -853 -5%
Stifel Financial
74
Stifel Financial
Missouri
$73.6K -$6.94K -1,352 -8%
ProShare Advisors
75
ProShare Advisors
Maryland
$70K +$72K +14,031 New

ALDX Hedge Fund Activity: Q4 2024 in Review

118 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q4 2024, worth a combined $186M — down 5.5% from $196M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ALDX positions and 16 closed out — a net gain of 8 holders — while 39 added to existing stakes and 24 trimmed.

The largest buyer was Ardsley Advisory Partners, adding an estimated $3.34M. The largest seller was Invesco, cutting an estimated $3.22M.

  • 118 institutional investors held Aldeyra Therapeutics (ALDX) as of Q4 2024, up from 112 in Q3 2024.
  • Funds reported $186M of Aldeyra Therapeutics stock for Q4 2024, down 5.5% quarter-over-quarter.
  • 24 funds opened new Aldeyra Therapeutics positions in Q4 2024 and 16 closed out, a net change of +8 holders.
  • The largest Aldeyra Therapeutics buyer in Q4 2024 was Ardsley Advisory Partners, an estimated $3.34M added.
  • The largest Aldeyra Therapeutics seller in Q4 2024 was Invesco, an estimated $3.22M sold.

Based on aggregated 13F filings for Q4 2024.